BIOMARKER and IMAGING CHARACTERISATION of INFLAMMATORY ATHEROMA in PATIENTS RECEIVING IMMUNOTHERAPY and ANGIOGENESIS INHIBITORS

Active, not recruitingOBSERVATIONAL
Enrollment

60

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

October 14, 2024

Study Completion Date

November 20, 2024

Conditions
CancerCardiotoxicityAtherosclerotic Disease
Interventions
DIAGNOSTIC_TEST

PET/CT with 18-FDG

"Study specific tests will include 18F-FDG PET/CT (specialised CT scan), electrocardiography (ECG), clinic blood pressure assessment, blood tests, urine sample, echocardiography (heart ultrasound) and tests on the fingertips (EndoPAT).~Positron emission tomography with computerised tomography (PET-CT) is a scanning technique in routine clinical use. It is the gold standard method for assessing blood vessel inflammation. A small amount of radioactive sugar (18F-FDG \[18F- fluorodeoxyglucose\]) is administered intravenously 90 minutes prior to the PET-CT scan. The distribution of uptake of this tracer is seen on the subsequent PET-CT scan. The CT component of this scan allows the PET image to be precisely aligned with anatomical structures (especially large blood vessels)."

Trial Locations (1)

G120YN

Beatson West of Scotland Cancer Centre, Glasgow

All Listed Sponsors
collaborator

Roche Diagnostics GmbH

INDUSTRY

collaborator

University of Glasgow

OTHER

lead

NHS Greater Glasgow and Clyde

OTHER